2018
Correlation of Prostate Cancer CHD1 Status with Response to Androgen Deprivation Therapy: a Pilot Study.
Tabakin A, Sadimin E, Tereshchenko I, Kareddula A, Stein M, Mayer T, Hirshfield K, Kim I, Tischfield J, DiPaola R, Singer E. Correlation of Prostate Cancer CHD1 Status with Response to Androgen Deprivation Therapy: a Pilot Study. Journal Of Genitourinary Disorders 2018, 2 PMID: 30714046, PMCID: PMC6358174.Peer-Reviewed Original ResearchMonths of ADTProstate cancerProstate-specific antigen (PSA) recurrenceSpecific antigen recurrenceAndrogen deprivation therapyAdditional larger studiesProstate cancer patientsLymph node tissueCHD1 deletionDeprivation therapySerum PSAAndrogen deprivationClinical outcomesCancer patientsImmunohistochemical stainsTissue microarrayNode tissueERG fusionLarger studyIndependent correlationTumor suppressor genePilot studyStrong associationPatientsProstatectomy
2012
Urinary exosomes as a stable source of mRNA for prostate cancer analysis.
Russo L, Bate K, Motamedinia P, Salazar G, Scott A, Lipsky M, Sadeghi N, Lin J, Comper W, Petrylak D, McKiernan J. Urinary exosomes as a stable source of mRNA for prostate cancer analysis. Journal Of Clinical Oncology 2012, 30: 174-174. DOI: 10.1200/jco.2012.30.5_suppl.174.Peer-Reviewed Original ResearchTransmembrane protease serine 2Androgen receptorERG fusionProstate cancer analysisUrinary exosomesPSA protein levelsUrine samplesPost-radical prostatectomyRandom urine samplesExpression of ERGRole of exosomesNEG patientsExosomal RNAPO patientsProstatic massageRP groupPatient discomfortPSA geneCancer analysisDiagnostic testingERG expressionNEG groupNon-invasive sourcePatientsMRNA biomarkers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply